The 5th Lipid Nanoparticles Development Summit Europe returns to Berlin at a pivotal moment for the field, as LNPs move beyond COVID-19 vaccines into broader therapeutic applications, including gene editing, oncology and in vivo cell therapy. This meeting brings together leading biotech, pharma and academic experts to tackle the biggest barriers preventing LNPs from reaching their full clinical potential.
What sets this event apart is its end-to-end focus, covering everything from early design and intracellular delivery, through analytical and CMC strategy, to regulatory alignment and scalable manufacturing. Unlike traditional meetings, it goes beyond well-known challenges to spotlight next-generation innovations, including extrahepatic targeting, hybrid nanoparticle systems and strategies for repeat dosing and reduced toxicity.
The timing couldn't be more critical. As the industry faces increasing scrutiny around safety, delivery precision and commercial viability, there is a growing need to align innovation with real-world application and regulatory expectations. This summit provides a unique platform to do exactly that, through expert-led sessions, interactive debates and practical case studies.
For anyone serious about advancing LNP-based therapeutics, this is the forum to
...
show more
The 5th Lipid Nanoparticles Development Summit Europe returns to Berlin at a pivotal moment for the field, as LNPs move beyond COVID-19 vaccines into broader therapeutic applications, including gene editing, oncology and in vivo cell therapy. This meeting brings together leading biotech, pharma and academic experts to tackle the biggest barriers preventing LNPs from reaching their full clinical potential.
What sets this event apart is its end-to-end focus, covering everything from early design and intracellular delivery, through analytical and CMC strategy, to regulatory alignment and scalable manufacturing. Unlike traditional meetings, it goes beyond well-known challenges to spotlight next-generation innovations, including extrahepatic targeting, hybrid nanoparticle systems and strategies for repeat dosing and reduced toxicity.
The timing couldn't be more critical. As the industry faces increasing scrutiny around safety, delivery precision and commercial viability, there is a growing need to align innovation with real-world application and regulatory expectations. This summit provides a unique platform to do exactly that, through expert-led sessions, interactive debates and practical case studies.
For anyone serious about advancing LNP-based therapeutics, this is the forum to gain clarity, challenge assumptions and accelerate progress.
URLs:
Website: https://go.evvnt.com/3625845-0?pid=1356
Tickets: https://go.evvnt.com/3625845-2?pid=1356
Brochure: https://go.evvnt.com/3625845-3?pid=1356
Date and Time: On Wednesday September 23, 2026 at 8:00 am to Thursday September 24, 2026 at 4:15 pm
Venue details: Dorint Kurfurstendamm Berlin, 41 Augsburger Str., Berlin, 10789, Germany
Category: Conferences | Science, Health and Medicine | Pharmaceuticals | Drug Development
Prices:
Drug Developer Pricing - Conference Only: EUR 2499.00,
Academic and Small Biotech Pricing - Conference Only: EUR 2099.00,
Solution and Service Provider Pricing - Conference Only: EUR 3099.00
Speakers: Ansgar Santel, Chief Executive Officer, Pantherna Therapeutics, Suzanne SaffieSiebert, Chief Executive Officer, SiSaf, Roy Pattipeiluhu, Director, Early-Stage Formulation Process Development, LNP Technology, BioNTech, Panagiota Papadopoulou, Marie Skłodowska-Curie Postdoctoral Fellow, National Hellenic Research Foundation, Heinrich Haas, Chief Technology Officer, NeoVac, Chuan-En Lu, Senior Scientist, Process Analytical Technology, Global Medicines Development, AstraZeneca, Dan Shores, Partner, Rothwell Figgs, Alexander Kros, Full Professor, Leiden University, Mengjie Shen, Scientist, Abogen Biosciences, Kamalinder Kaur Singh, Chair in Pharmaceutical Technology and Drug Delivery, School of Pharmacy and Biomedical Sciences, University of Central Lancashire, Mahdi Zeraati, Cancer Institute Fellow, University of Sydney, Pengbo Guo, Head of Product Development, CybernaX Biotechnologies, Shilpkala Gade, Higher Scientist, MHRA, Gholan Hamraz, PhD Candidate, BioNTech, Janos Szebeni, Group Head at the Department of Translational Medicine, Semmelweis University, Maria Irujo, Formulation and Pharmaceutical Innovation, Advanced BioDesign
show less
